Olaparib is a medication used to treat certain types of cancer. It works by blocking an enzyme that cancer cells need to repair their damaged DNA, which can help stop the cancer from growing. In this trial, researchers are studying how to optimize the dosing of olaparib by using a “boosting” approach, which means combining it with another substance that could help the body process the medication more effectively. This could potentially allow for lower doses while maintaining the same treatment effectiveness.

Pharmacokinetic booster (although not specifically named in the trial information) would be a substance used to enhance how the body processes olaparib. This approach is being studied to potentially improve how well patients tolerate the treatment while making it more cost-effective.

Cancer – A disease characterized by abnormal cell growth where cells divide uncontrollably and can invade nearby tissues. Cancer develops when the body’s normal control mechanism stops working, causing old cells to multiply uncontrollably instead of dying. These cells can form lumps or masses of tissue called tumors, which can grow and interfere with normal body functions. Cancer cells can break away from tumors and travel through the blood or lymph system to other parts of the body. The disease can start almost anywhere in the human body and can affect various organs and tissues.